News and Media

ProQR to Present at the Chardan Inaugural Gene Therapy Conference
LEIDEN, the Netherlands, Oct. 06, 2017 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq:PRQR), a company dedicated to changing lives through the creation of transformative RNA medicines for the treatment of severe genetic rare diseases including cystic fibrosis, Leber's congenital amaurosis 10 and dystro... 
ProQR Announces Positive Top-Line Results from a Phase 1b Study of QR-010 in Subjects with Cystic Fibrosis
Key updates QR-010 was observed to be safe and well-tolerated across all doses in this trial with no serious adverse events related to treatment. A clinically meaningful improvement of CF respiratory symptoms, as measured by CFQ-R RSS, was observed in 3 out of 4 multiple dose groups with a mean impr... 
ProQR Presents in vivo Proof of Concept Data for the Axiomer® RNA Editing Platform Technology
Key updates ProQR presents in vivo data in a relevant disease model, establishing proof of concept for its novel and proprietary Axiomer® RNA editing platform technology. Axiomer® technology Editing Oligonucleotides (EONs) recruit endogenous ADAR to make single nucleotide changes to RNA in a highly ... 
ProQR to Present at Two Investor Conferences in September
LEIDEN, the Netherlands, Sept. 21, 2017 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq:PRQR) today announced that the Company will present at two investor conferences during the month of September. Cantor Fitzgerald Global Healthcare Conference On Tuesday, September 26, 2017 at 9:10am ET, Daniel de... 
ProQR Receives Orphan Drug Designation from FDA for Drug Candidate QR-313 for Dystrophic Epidermolysis Bullosa and will Present Data at two Scientific Conferences
Key Updates ProQR’s drug candidate QR-313 for dystrophic epidermolysis bullosa (DEB) receives orphan drug designation from the FDA, representing the fifth program in the Company’s pipeline to receive ODD in the U.S. The Company will be presenting pre-clinical data for QR-313 at two European scientif... 
ProQR spins out Amylon Therapeutics as a privately-held company focused on central nervous system (CNS) therapeutics
Key updates ProQR spins out CNS-focused company, Amylon Therapeutics, with seed funding from a group of institutional and private investors. As part of the transaction, ProQR has granted an exclusive license to Amylon to develop therapeutics for beta amyloid related disorders and will be entitled to... 
ProQR’s Drug Candidate QRX-421 for Usher Syndrome Receives Orphan Drug Designation from FDA and EMA
Key Updates ProQR’s drug candidate QRX-421 for Usher syndrome receives orphan drug designation from the FDA and EMA, representing the third candidate in the company’s ophthalmology pipeline and the fourth in the broader pipeline to receive ODD in the U.S. and EU. There are currently no therapies com... 
ProQR Completes Dosing of Cystic Fibrosis Patients in QR-010 Phase 1b Trial
Key Updates Last patient received their final dose in the PQ-010-001 Phase 1b clinical trial of QR-010 in CF patients with the F508del mutation. Top-line trial data are expected to be issued in a press release post-market close on Monday, September 25, 2017, followed by a conference call. Adult C... 
ProQR Strengthens its Scientific Advisory Board with the Appointment of Dr. Phil Zamore, Dr. Cy Stein and Dr. Scott Armstrong
Key Updates ProQR appoints three new members to the Company’s Scientific Advisory Board: Dr. Phil Zamore, Dr. Cy Stein and Dr. Scott Armstrong, who bring a tremendous amount of experience in the fields of RNA-based therapeutics and genetic pediatric diseases. The new members will join Dr. Art Levin ... 
ProQR Announces Results for the Second Quarter of 2017
Key updates Data from two clinical trials of QR-010 presented at the European Cystic Fibrosis Conference.  Enrollment completed in the Phase 1b clinical trial in cystic fibrosis (CF) and top-line data expected to be announced in September. The Investigational New Drug Application (IND) and the Clini... 
ProQR’s Drug Candidate QRX-411 for Usher Syndrome Receives Orphan Drug Designation from FDA and EMA
Key Updates ProQR’s QRX-411 receives Orphan Drug Designation by the FDA and EMA for the treatment of retinitis pigmentosa, including Usher syndrome, the subtype targeted by QRX-411. Usher syndrome is an inherited condition that is characterized by combined deafness and blindness. QRX-411 targets the... 
ProQR R&D day Highlights Progress on Pipeline and Introduces Axiomer®, a novel proprietary RNA Technology
Key program features and updates: ProQR to host an R&D day in New York today, June 15, from 8:00am to 1:00pm Eastern Standard Time. The live webcast can be accessed at www.proqr.com/rd-day. Cystic Fibrosis (CF): Full data from the nasal potential difference (NPD) study for QR-010, ProQR’s lead m... 
ProQR to Participate in a Cystic Fibrosis Panel Discussion during the JMP Securities Life Science Conference
LEIDEN, The Netherlands, June 13, 2017 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq:PRQR) today announced that Daniel de Boer, Chief Executive Officer, will participate in a panel discussion focused on emerging treatment options in cystic fibrosis during the JMP Securities Life Science Conference on ... 
ProQR to present QR-010 data at the European Cystic Fibrosis Society Conference and provides an update on the ongoing Phase 1b trial
Key Updates An oral presentation on the final results from the proof-of-concept (PoC) nasal potential difference (NPD) trial will be given by Steve Rowe, MD at the European Cystic Fibrosis Society (ECFS) conference. Preliminary data from the Phase 1b study, PQ-010-001 single ascending dose (SAD)... 
ProQR Receives Fast Track Designation from the FDA for QR-110 for Leber’s Congenital Amaurosis Type 10
Key Updates ProQR receives Fast Track designation by the U.S. Food and Drug Administration (FDA). Closer interaction with FDA could potentially accelerate the development of QR-110 in patients with Leber’s Congenital Amaurosis Type 10 (LCA 10). LCA 10 is one of the most prevalent forms of gene-relat... 
ProQR Announces Results for the First Quarter of 2017
Key updates QR-010 Phase 1b clinical trial on track to present top-line data in cystic fibrosis (CF) patients in mid-2017. Investigational new drug (IND) application for QR-110, ProQR’s lead program in ophthalmology, was cleared by the FDA to start a clinical trial in both adult and pediatric LCA 10... 
ProQR remembers co-founder Henri Termeer after his unexpected passing
LEIDEN, the Netherlands, May 15, 2017 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq:PRQR), remembers co-founder and supervisory board member Henri A. Termeer, who unexpectedly passed away Friday May 12, 2017 at age 71 at his house in Marblehead, MA."We are devastated by the unexpected passing of o... 
ProQR Announces R&D Day in New York on June 15
Key updates: ProQR to host an R&D day in New York on June 15 from 8:00am to 1:00pm ET Presentations on development programs: QR-010 for cystic fibrosis, QR-110 for Leber’s congenital amaurosis Type 10 (LCA 10) and QR-313 for dystrophic epidermolysis bullosa (DEB) An update on the innovation/d... 
ProQR to Present its Ophthalmology Pipeline at ARVO, Highlighting Programs in Leber’s Congenital Amaurosis Type 10 (LCA 10) and Usher Syndrome
Key updates At ARVO ProQR will present additional positive pre-clinical proof-of-concept (PoC) data for QR-110 targeting LCA 10. The company has recently received IND clearance to start clinical trials for this program in both adult and pediatric patients. ProQR will also present data on its other c... 
ProQR Announces Clearance of IND Application to Start Clinical Trial for QR-110 in Leber’s Congenital Amaurosis Type 10 Patients
Key updates With the clearance of the investigational new drug (IND) application by the U.S. Food and Drug Administration (FDA), ProQR can now start clinical development of QR-110 in Leber’s congenital amaurosis Type 10 (LCA 10) patients LCA 10 is one of the most prevalent forms of gene-related blin... 
ProQR to Present at the Deutsche Bank Health Care Conference
LEIDEN, the Netherlands, April 20, 2017 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq:PRQR) today announced that Gerard Platenburg, Chief Innovation Officer, will present at the 42nd Annual Deutsche Bank Health Care Conference on Wednesday, May 3, 2017 at 12:50pm ET. The conference is being held at th... 
ProQR Announces Annual Meeting of Shareholders
LEIDEN, the Netherlands, April 10, 2017 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq:PRQR) today announced that the Annual General Meeting of Shareholders will be held on Wednesday, May 10, 2017 at 15:00 CET, at the offices of Allen & Overy at Apollolaan 15, 1077 AB Amsterdam, the Netherlands. ... 
ProQR Announces the Grant of two Key Patents, protecting QR-010 for Cystic Fibrosis in the US and EU
Key Updates ProQR received notice of grant for 2 key patents protecting QR-010 for CF in the US and EU until at least July 2033 QR-010 is currently being studied in 64 homozygous F508del patients in a Phase 1b safety, tolerability and exploratory efficacy trial. Top-line data to be reported in m... 
ProQR Appoints David M. Rodman, MD as Chief Development Strategy Officer
LEIDEN, the Netherlands, March 27, 2017 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq:PRQR) today announced that it appointed David M. Rodman, MD as Chief Development Strategy Officer. Dr. Rodman has had a long career in drug development including leadership roles in translational medicine, rare disea... 
ProQR to Present at Two Upcoming Investor Conferences in March
LEIDEN, the Netherlands, March 01, 2017 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq:PRQR), a company dedicated to changing lives through the creation of transformative RNA medicines for the treatment of severe genetic rare diseases including cystic fibrosis (CF), Leber's congenital amaurosis Type 10... 
ProQR Announces Results for the Fourth Quarter and Full Year 2016 and Provides a Business Update
Key updates Major progress in the QR-010 development program for CF with presentation of positive clinical data at North American CF conference in October 2016 On track to report data from the ongoing Phase 1b trial of QR-010 in mid-2017 Finalizing preparations to start a Phase 1b/2 trial of QR-1... 
On a Shared Quest to Find Treatments for Rare Diseases, ProQR Supports Rare Disease Day
LEIDEN, the Netherlands, Feb. 27, 2017 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq:PRQR), a company dedicated to changing lives through the creation of transformative RNA medicines for the treatment of severe genetic rare diseases including cystic fibrosis (CF), Leber's congenital amaurosis Type 10 ... 
ProQR to Present at the LEERINK Partners Global Healthcare Conference
LEIDEN, the Netherlands, Feb. 07, 2017 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq:PRQR), a company dedicated to changing lives through the creation of transformative RNA medicines for the treatment of severe orphan diseases such as cystic fibrosis (CF) and Leber's congenital amaurosis Type 10 (LCA1...